Publications by authors named "Ilenia Ferraro"
Article Synopsis
- Recognizing the cause of cerebral ischemic events is crucial for effective treatment and prevention, yet there are no standard MRI criteria to identify an embolic etiology.
- This study aims to analyze the MRI characteristics of ischemic brain lesions that occur after transcatheter ablation of atrial fibrillation (AF) by systematically reviewing various studies.
- Results show that 17.2% of patients developed ischemic lesions post-ablation, primarily small cortical lesions under 10 mm, mostly found in the middle cerebral artery region, with a very low rate of symptomatic issues.
Article Synopsis
- This study aimed to evaluate the safety and feasibility of starting sacubitril/valsartan therapy in patients with acute decompensated heart failure after they were stabilized in the hospital.
- Conducted over five years in two Italian medical centers, the study tracked patient outcomes, focusing on how many were discharged on the medication and any adverse events during and after hospitalization.
- Results showed that 91% of the 122 patients were discharged on sacubitril/valsartan, indicating that starting this treatment during hospitalization is both safe and practical for most patients.
Article Synopsis
- * A total of 341 patients were analyzed, with findings indicating that patients with elevated levels of both NPs and troponin had a significantly higher risk of death, even when adjusted for other health factors.
- * The results suggest that NPs can help identify patients at risk of poor outcomes, even in those with normal troponin levels, highlighting their potential as a useful biomarker in COVID-19 prognosis.
The optimal strategy for patients with an acute myocardial infarction (MI) and multivessel (MV) coronary artery disease complicated by cardiogenic shock (CS) remains unknown. We conducted a meta-analysis of all randomized controlled trials and observational studies that reported adjusted effect measures to evaluate the association of MV-PCI (percutaneous coronary intervention), compared with culprit only (C)-PCI, with cardiovascular events in patients admitted for CS and MV disease. We identified 12 studies (n = 1 randomized controlled trials, n = 11 observational) that included 7,417 patients (n = 1,809 treated with MV-PCI and n = 5,608 with C-PCI).
View Article and Find Full Text PDF